Journal
ALZHEIMERS & DEMENTIA
Volume 19, Issue 1, Pages 25-35Publisher
WILEY
DOI: 10.1002/alz.12614
Keywords
Alzheimer's disease; blood biomarkers; cardiovascular risk; risk stratification; vascular dementia
Categories
Ask authors/readers for more resources
This study aimed to investigate the association between blood biomarkers and Alzheimer's disease (AD) risk. It found that GFAP may be an early biomarker for AD, while p-tau181 and NfL are associated with intermediate risk. The impact of cardiovascular health on p-tau181 and NfL should be considered in risk stratification.
Introduction Blood biomarkers for Alzheimer's disease (AD) are the future of AD risk assessment. The aim of this study was to determine the association between plasma-measured phosphorylated tau (p-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) levels and risk of clinical AD incidence with consideration to the impact of cardiovascular health. Methods Within a community-based cohort, biomarker levels were measured at baseline using single molecule array technology in 768 participants (aged 50-75) followed over 17 years. Associations among biomarkers and AD, vascular dementia, and mixed dementia incidence were assessed. Results GFAP was associated with clinical AD incidence even more than a decade before diagnosis (9-17 years), while p-tau181 and NfL were associated with more intermediate AD risk (within 9 years). Significant interaction was detected between cardiovascular health and p-tau181/NfL. Discussion GFAP may be an early AD biomarker increasing before p-tau181 and NfL and the effect modifying role of cardiovascular health should be considered in biomarker risk stratification.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available